Accordingly, there is also evidence that MeCP2 levels are reduced in other neurodevelopmental disorders, including autism, trisomy 21, fragile X syndrome, Angelman syndrome, and Prader-Willi syndrome [37, 45]. This evidence concerns the gene MECP2 and neurodevelopmental disorder.